Former Novartis oncology chief Liz Barrett’s decision to jump ship to lead the biotech UroGen appears to have been vindicated after the company announced top-line results showing its lead drug could change standard of care in a form of urothelial can...
Original Article: UroGen's urothelial cancer drug hits target, could prevent surgery